Mayo Medical Laboratories

Mayo Medical Laboratories said this week that it has begun offering mass spec-based serum thyroglobulin testing using SISCAPA technology.

The Mayo Medical Laboratories will now offer Sequenom's MaterniT21 Plus test to patients at high risk for fetal chromosome abnormalities.

BioTheranostics said this week that Mayo Clinic and Mayo Medical Laboratories will offer the company's CancerType ID molecular cancer classification test to aid in the management of patients with metastatic cancer.

NEW YORK (GenomeWeb News) – Mayo Clinic and Mayo Medical Laboratories will offer BioTheranostics' CancerType ID molecular cancer classification test under a deal announced today.

The new test will be based on real-time PCR using fluorescence resonance energy transfer probes for detection.

The technology will allow Mayo to offer a test for M. tuberculosis complex speciation.

The eventual goal of the partnership would be to port the validated assay onto Rheonix's fully automated, modular molecular testing platform, which is still under development but may reduce the complexity and cost of warfarin sensitivity testing.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.

Retraction Watch's Ivan Oransky and Adam Marcus report that Harvard Medical School and Brigham and Women's Hospital have recommended that more than 30 papers from a former researcher be retracted.

Thomas Steitz, who won the 2009 chemistry Nobel Prize for his ribosome work, has died, the Washington Post reports.

In PLOS this week: mechanisms for genes implicated in coronary artery disease, rumen microbes and host genetics influence cow methane production, and more.